Nanosonics Limited · ASX:NAN
Nanosonics — Investor Presentation (May 2009)
25 slides from Nanosonics's investor presentation, May 2009
Slide 1: Investor Presentation
Investor Presentation David Radford - Executive Director and CEO May 2009
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs o
Slide 3: Key Investment Highlights
Key Investment Highlights Q3FY09 • Appointed extensive distribution network Europe/ANZ • TGA approval • Sales & Installation of first devices Australia • Trophon EPR finalist at Australian International Design Awards • Distribution partners identified in US and Canada Q4FY09 • FDA submission lodgmen
Slide 4: Nanosonics at a glance
Nanosonics at a glance Category Date Amount Total shares on issues @ 11 May 2009 195* million Share price @ 11 May 2009 A$ 0.32 Market capitalisation @ 11 May 2009 A$ 62.4 million Cash on hand @ 31 March 2009 A$ 16.1 million Cash burn @ 31 March 2009 A$ 1 million monthly * Including 92 million share
Slide 5: Our vision: Commercialising innovative solutions to global challenges
Our vision:Commercialising innovative solutions to global challenges “At Nanosonics our goal is simple, to safeguard the health and wellbeing of individuals, communities and environments by commercialising new standards in disinfection and sterilisation technologies” David Radford, CEO and Executive
Slide 6: Our business model: Australian innovation driving export growth
Our business model: Australian innovation driving export growth Research& Product Regulatory Product International Innovation design approval manufacture sales Australian innovation and technological leadership driving patented designs and manufacture into global markets
Slide 7: Real World Problems
t # ™ Real World Problems PEACE pros us dome ELC’ M Sport Business Comment Travel Lifestyle Culture lebrities Obituaries Weird Science Earth Topics World — Poiltics auare here: Home > News > World News > Europe 3train of super- C.diff ‘spreading across UK and Europe’ \ highly virulent strain of dead
Slide 8: Trophon - A breakthrough in the world of medical disinfection
Trophon - A breakthrough in the world of medical disinfection
Slide 9: Trophon EPR - A breakthrough in the world of medical disinfection
Trophon EPR - A breakthrough in the world of medical disinfection “The Trophon EPR will make the task of disinfecting ultrasound transducers significantly faster, safer and more convenient and it is easily integrated into current medical practices and procedures” Dr Michael Cooper, Head of Gynaecolo
Slide 10: Setting a new standard
Setting a new standard Trophon EPR – your one-stop solution for HIGH LEVEL DISINFECTION+ se r t c o untr y> r m at io n in <in of intracavity and surface ultrasound transducers r o rd e r ing in fo ler n a m e> at o a F n ta c t < insert de o please c u m ber>. o n e n <insert ph HLD+ Sporicidal eff
Slide 11: Comparative ultrasound probe disinfection methods
Comparative ultrasound probe disinfection methods Current Future
Slide 12: Latest USA CDC guidelines
Latest USA CDC guidelines • Supports the need for HLD for intracavity ultrasound probes between patients • Supports that aldehydes residues may be toxic for use in certain endo-vaginal procedures, particularly to embryos • States that aldehydes damage ultrasound probes even though manufacturers have
Slide 13: NanoNebulant proven sporicide
NanoNebulant proven sporicide • NanoNebulant achieves > 6 log reduction of Clostridium difficile spores in Trophon EPR • No surviving micro-organisms were identified • Test was performed to agreed international standards Current methods Trophon EPR
Slide 14: Product roll-out strategy Australia
Product roll-out strategy Australia • First product placement - March 2009 • Controlled release into Australia and New Zealand • Customer feedback • Easy to use • Removes OH&S issues • Quick and effective • Fits well in clinical practice First order: David Singe - Chief MIT at Maryborough District H
Slide 15: Product roll-out strategy Europe
Product roll-out strategy Europe • Product launch on track for Q4FY09 • Hospital acquired infections continue to drive the need across Europe • Strong demand for Trophon EPR from France • Recent issues with hospital acquired infections from ultrasound probes • National move banning gluteraldehyde in
Slide 16: Product roll-out strategy North America
Product roll-out strategy North America • Pending approval FDA 510(k) submission • Trophon EPR will be launched concurrently in USA & Canada • Advanced discussions with potential distributors for USA/Canada, appointment by Q2FY10 • Market opportunities • > 70,000 Imaging Clinics • Replacement of GUS
Slide 17: Target Market Size
Target Market Size Total Total Country/ Radiology O&G Other targeted available Region intracavity intracavity targeted market market ANZ 0.5M 1M 0.2M 1.7M 5.8M Europe 7M 16M 3M 26M 70M Canada 0.4M 0.9M 0.2M 1.5M 3.6M US 7M 11M 9M 27M 87M Asia 8.2M 17M 22M 47.2M 215M Japan 3.4M 13M 12M 278.4M 76M Tot
Slide 18: Appointment of distribution channels
Appointment of distribution channels Appointed Appointed In progress Australia UK Asia Region New Zealand Benelux Japan France Spain USA Germany Poland Canada Italy Russia Scandinavia Portugal Switzerland
Slide 19: Regulatory update
Regulatory update <+1,"=6>?@(2?,(;6 !1#2?,(6AB064(C12+#B0D I?0(56J"+,KL56 8J.6F6S+,+K+ .1;#0?+56JM?#N56 O2+1,"=6!"#6T6 :#+2D6 `B,K10+; +?@6AB06;+2(;6'("R O+;6K(P?"(;6+P+?2+Q2(R S+0?QQ(+, E+0$%- J(/$%- _?0C?,6:;2+,K; .1;#FGH ./0$%- J+1K?6.0+Q?+ 34567(056 J/+?, .0C(,#?,+ *12$%- Y0+N?26 89 UB0#1C+2 :;0
Slide 20: Production capacity
Production capacity Manufacturing roll-out strategy is; • Flexible • Initially in-house • Scalable • Handle volume increases • Transferable • Can be relocated • Responsive • Rapid handling of demand fluctuations
Slide 21: Expanding the product range
Expanding the product range NanoNebulant technology is transferable and highly scalable to other applications Food applications Platform technology Scaleable Room / Industrial Cost effective Medical /Healthcare Environmentally friendly
Slide 22: Endoscope/TEE disinfection
Endoscope/TEE disinfection • Accelerated development using existing technologies • Based on proven NanoNebulant technology • Regulatory approval for TEE variant based on Trophon EPR • Current test results meet required specifications • prototyping • testing • Market potential in excess of AU$200M •
Slide 23: Hospital and Community Acquired Infections
Hospital and Community Acquired Infections • Hospital acquired infection (HAI) and Community acquired infections (CAI) increasingly prevalent • Pandemic risks continuing to evolve e.g. H1N1 flu • Major cross-contamination risks include hand washing, hospital beds, phones and computers • Opportunitie
Slide 24: Key Investment Highlights
Key Investment Highlights Q3FY09 • Appointed extensive distribution network Europe/ANZ • TGA approval • Sales & Installation of first devices Australia • Trophon EPR finalist at Australian International Design Awards • Distribution partners identified in US and Canada Q4FY09 • FDA submission lodgmen
Slide 25: i
i